IHAM
ALT icon

Integral Health Asset Management’s Altimmune ALT Stock Holding History

Integral Health Asset Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-160,000
Closed -$1.58M – 74
2021
Q2 		$1.58M Buy
+160,000
New +$2.19M 0.43% 58

Other funds holding ALT

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Integral Health Asset Management's ALT Position: Q3 2021 in Review

Integral Health Asset Management sold out of Altimmune (ALT) in Q3 2021, closing a stake of 160,000 shares — an estimated $1.58M sold.

Integral Health Asset Management first reported a position in ALT in Q2 2021 and held it in 1 quarter. The position peaked at $1.58M in Q2 2021. 118 funds tracked by Wall St. Rank hold ALT as of Q3 2021.

  • Integral Health Asset Management reported no remaining Altimmune position as of Q3 2021 after selling out during the quarter.
  • Integral Health Asset Management sold 160,000 Altimmune shares in Q3 2021, an estimated $1.58M.
  • Integral Health Asset Management first reported a position in Altimmune in Q2 2021 and held it in 1 quarter.
  • Integral Health Asset Management's Altimmune position peaked at $1.58M in Q2 2021.
  • 118 funds tracked by Wall St. Rank held Altimmune as of Q3 2021.

Based on Integral Health Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.